|
|
||||||||
AJP - Heart and Circulatory Physiology, Vol 259, Issue 5 1613-H1617, Copyright © 1990 by American Physiological Society
ARTICLES |
L. M. Bradley, J. F. Czaja and R. E. Goldstein
Department of Anesthesiology (Critical Care Medicine), Children's National Medical Center, Washington, DC.
Endothelin, a recently described endothelial cell-derived peptide, produces pulmonary and coronary vasoconstriction in mature animals. We investigated the acute hemodynamic effects of porcine endothelin in 14 anesthetized open-chest new-born piglets during normoxia (Pao2 = 102 +/- 5 mmHg) and hypoxia (fractional inspired O2 concentration = 0.12 X 15 min, Pao2 = 31 +/- 1 mmHg). Six of these animals were pretreated with indomethacin, a cyclooxygenase inhibitor. Low-dose (100 pmol/kg) intravenous bolus injection of endothelin decreased pulmonary vascular resistance index (PVRI) (42 +/- 6 to 16 +/- 4 mmHg.l-1.min.kg, P less than 0.01) and increased coronary blood flow (CBF) (17 +/- 2%, P less than 0.01); cardiac index (CI) and coronary vascular resistance were unaffected. The pulmonary and coronary responses to endothelin were preserved during hypoxia: PVRI fell (160 +/- 22 to 83 +/- 13 mmHg.l-1.min.kg, P less than 0.05) and CBF rose (35 +/- 11%, P less than 0.05). Low-dose endothelin moderately increased mean arterial pressure (61 +/- 3 to 75 +/- 6 mmHg, P less than 0.05) and systemic vascular resistance index (SVRI) (375 +/- 23 to 491 +/- 41 mmHg.l-1.min.kg, P less than 0.01). High-dose (1,000 pmol/kg) endothelin mildly decreased PVRI (51 +/- 7 to 35 +/- 12, NS), moderately increased SVRI (375 +/- 45 to 594 +/- 95 mmHg.l-1.min.kg, P less than 0.05), and markedly diminished CBF (-54 +/- 6%, P less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
![]() |
P. W. Domkowski, J. T. Cockerham, P. A. Kot, J. L. Myers, and R. A. Hopkins Characterization of the pulmonary arterial response to endothelin-1 and bosentan in neonatal pigs Ann. Thorac. Surg., November 1, 2000; 70(5): 1522 - 1530. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Pearl, S. A. Wellmann, J. L. McNamara, J. P. Lombardi, C. J. Wagner, J. L. Raake, and D. P. Nelson Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function Ann. Thorac. Surg., November 1, 1999; 68(5): 1714 - 1721. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Holm, J. Liska, M. Clozel, and A. Franco-Cereceda THE ENDOTHELIN ANTAGONIST BOSENTAN: HEMODYNAMIC EFFECTS DURING NORMOXIA AND HYPOXIC PULMONARY HYPERTENSION IN PIGS J. Thorac. Cardiovasc. Surg., October 1, 1996; 112(4): 890 - 897. [Abstract] [Full Text] |
||||
![]() |
M. Okada, C. Yamashita, M. Okada, and K. Okada Role of Endothelin-1 in Beagles With Dehydromonocrotaline-Induced Pulmonary Hypertension Circulation, July 1, 1995; 92(1): 114 - 119. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |